263 related articles for article (PubMed ID: 27416087)
1. Novel melanoma therapies and their side effects.
González N; Ratner D
Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
[TBL] [Abstract][Full Text] [Related]
2. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
3. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
4. Managing the skin toxicities from new melanoma drugs.
Mavropoulos JC; Wang TS
Curr Treat Options Oncol; 2014 Jun; 15(2):281-301. PubMed ID: 24867225
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
[TBL] [Abstract][Full Text] [Related]
9. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
10. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
11. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
[No Abstract] [Full Text] [Related]
12. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
13. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
14. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
Stefanou MI; Gepfner-Tuma I; Brendle C; Kowarik M; Meiwes A; Eigentler T; Müller A; Garbe C; Ziemann U; Tabatabai G; Forschner A
J Dtsch Dermatol Ges; 2020 Feb; 18(2):136-139. PubMed ID: 31814289
[No Abstract] [Full Text] [Related]
15. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
17. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.
Fujimura T; Kambayashi Y; Hidaka T; Tamabuchi E; Otake E; Tono H; Mizuashi M; Furudate S; Aiba S
J Dermatol; 2018 Feb; 45(2):e35-e36. PubMed ID: 28983948
[No Abstract] [Full Text] [Related]
18. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
19. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
[TBL] [Abstract][Full Text] [Related]
20. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.
Flaherty DC; Hoffner BW; Lau BJ; Hamid O; Faries MB
J Surg Oncol; 2015 Dec; 112(8):844-5. PubMed ID: 26503563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
